undamentalytics Newsletter
Sign in

Apnimed, Inc. (APMD) stock

Add to watchlist

Add holding +

NASDAQ: APMD Nasdaq Biotechnology Next results ~November 11, 2026

Apnimed, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Model estimate per share

~$9.4

Valuation models combined (2)

Base case. Range ~$8.2–$14. Weighted average of 2 models (growth cash-flow model, forward price-to-sales vs peers), the growth cash-flow model counting double.

Price vs value

No Buy/Hold/Sell rating is issued: limited reported history: available models are shown without a Buy/Hold/Sell rating.

Apnimed, Inc. valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders2 buying, 0 selling2 purchases and 0 sales by directors and officers, last 12 monthsInsider trades

The Fundamentalytics view

Next results ~November 11, 2026 (estimated)

Current signal Results well short of expectations: Reported earnings per share missed the analysts' consensus estimate by 22% in the quarter to 2026-06-30.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Latest results

Earnings per share
-$0.42 against an average estimate of -$0.34: missed by 22.5%
Share reaction
+2.3% in the first session after the results on September 8, 2026, against -1.0% for the S&P 500
Next report
November 11, 2026; average EPS estimate -$0.60

Apnimed's figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-6.1%
  • 1 week-18.7%
  • 1 month-28.4%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Earnings

Last results
September 8, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Results
  2. Governance
  3. Insider trade

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Apnimed, Inc. valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: limited reported history: available models are shown without a Buy/Hold/Sell rating.

Valuation models

We value Apnimed, Inc. as an operating company, with every model that fits that kind of business. Cost of equity 9.9%: the 10-year Treasury yield (4.9%) plus a beta of 1.1 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Growth cash-flow model Revenue for this year and next from analysts' consensus, then growth fading to 2.5%; the operating margin moving to profitable peers'; investment needed per dollar of growth from peers; reduced by a failure probability. For young or fast-growing companies. The starting margin is normalized to between -100% and 60%; net margin is a proxy when operating income is not tagged. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$8.2 ~$8.1–$9.0 Primary model, counts double
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: no twelve-month earnings or share count in the filings yet
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: no twelve-month earnings or share count in the filings yet
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: no twelve-month earnings or share count in the filings yet
Forward price-to-sales vs peers Next year's consensus sales per share times peers' typical forward price-to-sales; only when earnings are negative. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$14 ~$15–$56 Included, half weight
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. — Does not apply: revenue and margins don't support a positive value
Combined value Weighted average of the models that apply: the primary model (growth cash-flow model) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. ~$9.4 ~$8.2–$14 2 models

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Apnimed, Inc. with Biotechnology in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 11, 2026, after the close. Analysts expect revenue of $0 and EPS of −$0.60 (range −$0.61 to −$0.59) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$0.06 — $91m —
Next −$3.98 −6525% $22m −75%

How the EPS forecast has moved

In the last 30 days, 0 analysts raised Apnimed, Inc.'s forecast and 0 cut it.

Consensus EPS forecast Apnimed, Inc., last 90 days
−$4.00 −$3.00 −$2.00 −$1.00 $0.00 30 days ago 7 days ago Now Next fiscal year, 30 days ago: −$3.98 Next fiscal year, 7 days ago: −$3.98 Next fiscal year, Now: −$3.98 −$3.98

Average of analysts' published estimates (third-party data).

View chart data
Period Next fiscal year
30 days ago −$3.98
7 days ago −$3.98
Now −$3.98

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$0.34 −$0.42 −22.5%

Adjusted EPS as companies report it, against the average analyst estimate.

Analyst recommendations

4 analysts, Oct 2026
Buy4100%
Hold00%
Sell00%

Monthly trend

  1. Oct 202644
  2. Sep 202644
  3. Aug 202644

Counts of recommendations published by analysts covering Apnimed, Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
—
of tradable shares
Days to cover
2.78
at average volume
Short interest, 1 month
+105%
to October 15, 2026
Held by institutions
25%
of shares
Held by insiders
35.6%
of shares
Employees
81
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Price behaviour

52-week range
Not enough history
From 52-week high
—
vs 50-day average
−32.1%
vs 200-day average
—
Volatility (1 year)
—
Beta vs S&P 500
—

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
1 up, 0 down
typical move ±2.3%
After a week
0 up, 1 down
typical move ±6.9%
After a month
0 up, 1 down
typical move ±34.3%
Results releasedNext dayS&P 500 next day5 days21 days
September 8, 2026 +2.3% −1.0% −6.9% −34.3%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Fundamentals

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-Q. Generated November 3, 2026. Definitions in our methodology.

Insider trading activity

Full insider history and chart
Insider purchases History → $5.2M 2 trades by 2 insiders, last 12 months Insider sales History → $0 0 trades by 0 insiders
Net ▲ $5.2M net buying
Insider Date Trade Shares Price Value
Sekhri Paul J Director August 3, 2026 Buy 12,500 $16.00 $200,000
Morningside Venture Investments Ltd 10% owner August 3, 2026 Buy 312,500 $16.00 $5M

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

  • September 8, 2026

Recent SEC filings

Data status

When each part of this page on Apnimed, Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Apnimed, Inc. in brief

What does Apnimed, Inc. do?
Apnimed, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
What is Apnimed, Inc.'s stock ticker?
Apnimed, Inc. trades under the ticker APMD on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
Are insiders buying or selling Apnimed, Inc. stock?
Over the last 12 months, Apnimed, Inc.'s directors and officers reported 2 open-market purchases and 0 sales on Form 4. The insider trading page charts every trade.
When is Apnimed, Inc.'s next earnings date?
Around November 11, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Apnimed, Inc. announces its own schedule.